Mitsubishi Tanabe pulls Radicava MAA for ALS in the Europe

30 May 2019

Mitsubishi Tanabe Pharma (TYO: 4508; MTPC) announced today the withdrawal of the Marketing Authorization Application (MAA) of Radicava (edaravone) for the treatment of amyotrophic lateral sclerosis (ALS) in the European Union (EU).

The edaravone MAA was submitted in 30 April 2018 by Mitsubishi Tanabe Pharma Europe, the MTPC R&D subsidiary in the EU. Edaravone (named Radicut BAG for IV Infusion 30mg in Japan) is an intravenous treatment for ALS, a rapidly progressive neurological disease.

Edaravone has been approved for treatment of ALS in Japan, South Korea, the USA, Canada and Switzerland, based on the results from a six-month placebo-controlled study in Japanese ALS patients, in which the primary endpoint was the ALS functional rating scale (ALSFRS-R), a measurement of functional loss in daily living activities in ALS patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK